TICKERNERD
Menu
SNYRSNYRHealthcare · Medical Distribution

SNYR Stock Forecast: Synergy CHC Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.10

The 2 Wall Street analysts covering Synergy CHC Corp. hold a median 12-month price target of $3.75 — +3616.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$1.5M
Ticker Nerd rank
53 / 100
Median analyst target
$3.75
Analysts covering
2
Revenue$5.5M−32.8% y/y
Operating income−$567K
Net income−$2.6M
Free cash flow−$2.0M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Ticker Nerd rank

SNYR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Synergy CHC Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
100
Accruals
90
Volatility
59
Issuance
55
Value
47
Revisions
45
Quality
40
Growth
29
Momentum
21

Size (100): Smaller than most of the companies we track.

Momentum (21): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SNYR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SNYR, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $3.75Median $3.75High $3.75

The green dot is the last close — the median target sits +3616.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 June 2026Ascendiant CapitalMaintainsBuy—
10 June 2026Ascendiant CapitalMaintainsBuy$5.50 → $3.75
14 Apr 2026Ascendiant CapitalMaintainsBuy—
2 Feb 2026Ascendiant CapitalInitiatesBuy—
14 Nov 2025Roth CapitalMaintainsBuy—
21 Jan 2025Roth MKMInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNYR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SNYR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−161.3%
Analysts raising
0
Analysts cutting
1
Fundamentals

Synergy CHC Corp. (SNYR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.9×

Cheaper than 67% of US stocks

Price / sales
0.0×

Cheaper than 98% of US stocks

Price / book
−0.0×

Cheaper than 93% of US stocks

EV / EBITDA
−2.7×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
−32.8%

Higher than 8% of US stocks

Earnings growth (YoY)
−32.8%

Higher than 14% of US stocks

Gross margin
72.3%

Higher than 85% of US stocks

Operating margin
−10.3%

Higher than 24% of US stocks

Net margin
−57.0%

Higher than 9% of US stocks

Returns & dividend
Return on equity
53.4%

Higher than 93% of US stocks

Return on assets
−62.0%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Synergy CHC Corp. (SNYR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Synergy CHC Corp. has a market value of $1.5M and an enterprise value of $29.0M.

  • Revenue in the twelve months to 31 Mar 2026: $27.7M. The latest quarter shrank 32.8% year on year.

  • Net income over the same four quarters: −$15.8M, a −57.0% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$3.8M.

  • Shares outstanding: 11.3M.

  • Trailing P/E: 3.9×; forward P/E: 0.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Synergy CHC Corp. employs 28 people — $989K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

SNYR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
SNYRSynergy CHC Corp.$1.5M
53
MEDSDataMeds AI, Inc.$4.2M
15
COSMCosmos Health, Inc.$22.3M
19
HELPCybin, Inc.*$1.4M
42
BBLGBone Biologics Corp.*$1.7M
23
AEMDAethlon Medical, Inc.*$1.9M
25
MNDRMobile-health Network Solutions*$2.0M
13

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Synergy CHC Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SNYR news & analysis

Synergy CHC Corp. Announces Receipt of Nasdaq Letter

GlobeNewsWire · 21 Aug 2026negative

Synergy CHC Corp. disclosed that it received a notice from Nasdaq on August 20, 2026, indicating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it delayed filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 with the SEC.

Why it matters — A Nasdaq non-compliance notice over a delayed SEC filing raises potential listing-status and regulatory concerns for SNYR shareholders.

FAQ

Frequently asked questions about SNYR stock

What is the SNYR stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Synergy CHC Corp. have a median 12-month price target of $3.75, with estimates ranging from $3.75 to $3.75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SNYR stock a buy right now?

Of the 2 analysts covering Synergy CHC Corp., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Synergy CHC Corp. 53 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SNYR?

As at 22 Aug 2026, Synergy CHC Corp. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).

Will SNYR stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +3616.6% from the last close, and Ticker Nerd's factor model ranks Synergy CHC Corp. 53 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SNYR stock forecast for 2030?

No analyst covering Synergy CHC Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNYR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.75 to $3.75 over the next 12 months.

What does Synergy CHC Corp. do?

Synergy CHC Corp. is an innovative company that specializes in marketing and distributing consumer healthcare products.

What is the latest news on SNYR?

The most recent item we track (GlobeNewsWire, 21 Aug 2026): "Synergy CHC Corp. Announces Receipt of Nasdaq Letter". Synergy CHC Corp. disclosed that it received a notice from Nasdaq on August 20, 2026, indicating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it delayed filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 with the SEC.

Company

About Synergy CHC Corp.

Synergy CHC Corp. is an innovative company that specializes in marketing and distributing consumer healthcare products. Its product portfolio encompasses a wide range of health and wellness categories, including dietary supplements, skin care, and over-the-counter remedies. The company's primary function is to develop and promote products that cater to the increasing consumer demand for health-conscious options that support active lifestyles. Synergy CHC Corp. actively participates in the consumer healthcare sector by striving to deliver effective, high-quality products using both traditional and digital marketing strategies. With its presence in multiple international markets, the company seeks to leverage global consumer trends towards wellness and preventive health. Synergy CHC Corp.'s contribution to the financial market is significant as it provides investors with exposure to the rapidly growing health and wellness industry, characterized by strong consumer interest and expansive opportunities for product innovation and market expansion.

CEO Mr. Jack Ross · 28 employees · United States · https://synergychc.com